特异性COX-2抑制药的临床应用及其前景

特异性环氧化酶-2(COX-2)抑制药为一组新的非甾体类抗炎药(NSAIDs)，此类药能阻止前列腺素合成，但不阻止由COX-1激活的前列腺素类物质的合成。COX-2抑制药能迅速提供镇痛，对骨关节炎和类风湿性关节炎的抗炎镇痛效应相当于非特异性NSAIDs的标准剂量，而其胃肠道副作用较低，其他不良反应与非特异性NSAIDs相似。

Clinical application and foreground of specific cyclooxygenase-2 inhibitors

Specific cyclooxygenase-2(COX-2) inhibitors constitute a new group of non-steroidal antiin-flammatory drugs (NSAIDs) which, at recommended doses, block prostaglandin production by cyclooxygenase-2, but not by cyclooxygenase-1. COX-2 inhibitors act rapidly in providing pain relief and their anti-inflammatory analgesic effect in osteoarthntis and rheumatoid arthritis is equivalent to standard doses of non-selective NSAIDS. COX-2 inhibitors show significantly lower incidences of gastrotoxicity than non-selective NASIDs. Other adverse effects, such as interference with antihypertensive agents and the potential to produce renal dysfunction in patients with compromised renal function by COX-2 inhibitors, seem similar to those of non- selective NASIDs.